Lilly commits further to genetic medicine with $700 million Boston site spend

23 February 2022

US drugmaker Eli Lilly (NYSE: LLY) has announced the launch of the Lilly Institute for Genetic Medicine with an investment of approximately $700 million to establish a facility at a new site in the Boston Seaport.

This investment is part of the company's strategy to advance RNA based therapeutics and builds on the acquisition and rapid expansion of Prevail Therapeutics, a gene therapy pioneer based in New York City.

Lilly bought Prevail – a biotech company developing potentially disease-modifying AAV9-based gene therapies for patients with neurodegenerative diseases – for around $1 billion in December 2020.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK